Video

Rosalind Kalb from the National Multiple Sclerosis Society: Treating Advanced Disease in Multiple Sclerosis

Author(s):

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Rosalind Kalb, PhD, from the National Multiple Sclerosis Society discussed this issue during the annual meeeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland. Kalb said that while there may be disagreement on what qualifies as advanced disease there is no question that patients in this classification need a specialized level of care through the later stages of their disease.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.